Nordic Nanovector’s mission is to extend and improve the lives of patients with haematological cancers by developing and commercialising innovative Antibody Radionuclide Conjugates (ARC).
The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody Radionuclide Conjugates (ARCs), designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities.
Nordic Nanovector was established in 2009, leveraging expertise in targeted cancer therapy from the Norwegian Radium Hospital, and has its main office and laboratories in Oslo, Norway.
Events and Highlights
23 November 2016
Quarterly Report Q3-2016